Key Market Movers: Technology Giants and Pharmaceutical Companies Under Spotlight

While UK markets were closed Monday for the Easter bank holiday, US equities experienced a significant downturn following critical remarks from the president regarding Federal Reserve policy. The selling pressure affected several major corporations that have been trending among investors this week.

The criticism centered on interest rate policy, with the president suggesting that rates remained too high. Through a social media post, he called for "pre-emptive" rate cuts, arguing that inflation was no longer a significant concern.

"With these costs trending so nicely downward, just what I predicted they would do, there can almost be no inflation, but there can be a SLOWING of the economy unless Mr. Too Late, a major loser, lowers interest rates, NOW," the president stated on his Truth Social platform.

Market Response and Expert Analysis

The presidential comments triggered immediate market reactions. The S&P 500 closed Monday's session down 2.4%, while the tech-focused Nasdaq slid 2.6% and the Dow Jones Industrial Average fell 2.5%. Leading semiconductor manufacturer Nvidia was caught in the downdraft, declining 4.5% during the session.

Richard Hunter, head of markets at Interactive Investor, offered analysis on the situation: "Not content with rattling foreign powers, domestic consumers and investors, the president launched another salvo on the Federal Reserve chair which sent markets lower again. It is unclear whether there is constitutional room to remove the Fed chair early, but in any event the attack does little to improve the reputation of the US at a time when the validity of traditional havens such as the dollar and Treasuries are being brought into question."

Tesla Faces Pressure Ahead of Quarterly Results

The electric vehicle manufacturer's shares dropped 5.8% during Monday's session, adding to recent difficulties. The company is scheduled to report first quarter results on Tuesday after market close, amid challenges including disappointing delivery numbers and controversy surrounding its CEO's political activities.

Earlier in April, the automaker reported first quarter global deliveries of 336,681 vehicles, significantly below analyst expectations of 390,342 according to Bloomberg consensus estimates. This represents the company's worst delivery performance since the second quarter of 2022.

Additionally, protests have emerged at showrooms worldwide regarding the CEO's role in heading the Department of Government Efficiency (DOGE) and overseeing potential government agency reductions.

Matt Britzman, senior equity analyst at Hargreaves Lansdown, noted that "revenue is expected to come in broadly flat year-on-year, with a drop in earnings as Tesla transitioned to the refreshed version of its best-selling car, the Model Y."

Roche Announces Major US Investment

The Swiss pharmaceutical giant's shares remained relatively stable after announcing plans to invest $50 billion in pharmaceuticals and diagnostics operations in the United States over the next five years. The investment includes new research and development facilities, along with expanded manufacturing capacity in Indiana, Pennsylvania, Massachusetts, and California, with another site to be announced.

According to the company, this investment will create more than 12,000 new jobs and position the company to export more medicines from the US than it imports. The announcement comes amid concerns about potential tariffs on pharmaceutical imports to the United States, with the administration having indicated that such duties would be announced "very shortly."

Novo Nordisk Faces Competitive Pressure

Shares in the Danish pharmaceutical company fell 7.4% in Tuesday morning trading following positive trial results from competitor Eli Lilly's weight-loss pill. Eli Lilly reported that its orforglipron pill "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines" in phase three trials.

David A. Ricks, Eli Lilly chair and CEO, commented: "As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world."

The favorable results appeared to raise investor concerns about potential threats to Novo Nordisk's popular injectable weight-loss treatments Ozempic and Wegovy.

Fresnillo Benefits from Gold Price Surge

The precious metals mining company emerged as the top gainer on the FTSE 100 Tuesday morning, rising nearly 3% as gold prices reached new records, briefly exceeding $3,500 per ounce.

Investors have increasingly turned to gold amid uncertainty surrounding tariff policies and monetary policy criticism. Gold is traditionally viewed as a safe-haven asset during periods of market turbulence.

Russ Mould, investment director at AJ Bell, explained: "If the administration is able or willing to follow through on its threat to fire Fed chair Jerome Powell before his term is up next year, it could provoke an even stronger reaction amid fears about the implications for inflation. US currency and government debt are often a safe haven during times of market turbulence but, with America the source of much of the recent volatility, investors have been reaching for another obvious port in the storm, gold, in large numbers."